Clinical Trial Update: DARA RVD For High Risk SMM [Phase 2]

View source ↗

Summary

A Phase 2 trial investigates adding daratumumab to the RVD regimen for high-risk Smoldering multiple myeloma and multiple myeloma; the study is currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (Darzalex) (daratumumab)
• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: Omar Nadeem, MD | Conditions: High-risk Smoldering Multiple Myeloma, Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING